Introduction
Cyclosporine A (CsA) is a calcineurin inhibitor which has considerably improved graft outcome in solid organ transplantation.
However, its clinical benefits are balanced by its side effects, mainly chronic nephrotoxicity which remains a major problem in all types of solid organ transplantation ( ). CsA is a substrate of the efflux transporter P-glycoprotein (P-gp; gene) extruding xenobiotics 1 ABCB1
from the cell ( ). The most frequent polymorphisms of are located in exons 12 (1236 C>T), 21 (2677 G>T) and 26 (3435 C>T).
ABCB1
There have been few studies investigating the consequences of polymorphisms on the efficacy or toxicity of immunosuppressive ABCB1 therapy in renal transplantation. Crettol et al. described higher cyclosporine concentrations in the lymphocytes of carriers of the variant 3435T allele ( ) suggesting that P-gp could influence CsA activity independently of its effect on the drug bioavailability or ABCB1 3
clearance. However, only a weak association was found between the recipient s haplotype gathering the exon 12, 21 and 26 alleles ' ABCB1 and acute graft rejection, and no association with graft loss ( ). The impact of the silent 3435 C>T SNP on the pharmacokinetics of CsA is 4 controversial ( ). It has been argued that mRNA stability would be lower when the 3435-T allele is present at exon 26 ( ), or that 5 ABCB1 6
P-gp conformation would be altered as a result of this silent mutation, the rarity of the corresponding codon affecting the timing of cotranslational folding and insertion of P-gp into the membrane ( ). Since P-gp is highly expressed in renal proximal tubule epithelial 7 cells ( ), its activity in the kidney graft, which carries the donor s and not the recipient s genome, may contribute to CsA toxicity. This was 8 than that of CYP3A5 (when expressed) and that the oxidative metabolism of CsA in human renal microsomes is strongly dependent to CYP3A5 activity ( ). It is thus possible that the donor s status for CYP3A5 could also have a role in the accumulation, hence 11 -13 ' in situ local toxicity, of CsA.
The goal of this study was to investigate the influence of the donor s polymorphisms in and on graft loss in a large
retrospective cohort with a long-term follow-up of renal transplant recipients given CsA.
Results

Clinical data
Clinical and demographic characteristics of the 259 recipients who fulfilled the inclusion and exclusion criteria are reported in Table 1 . graft losses (7.7 of recipients) were observed in this cohort within the period considered ( ).
% Table 1 Genotype/haplotype distribution and association with graft loss
Genotyping results were in the Hardy-Weinberg equilibrium and similar to those reported in the literature ( ) ( ). As 14 Table 2 previously described, a strong LD was observed between exons 12, 21, Univariate analysis showed that patients who received their graft from donors carrying the variant 1236 TT, 2677TT and ABCB1
3435TT genotypes had an increased risk of graft loss ( ) compared to patients whose donors were carriers of the wild-type Table 3 genotypes (CC1236, GG2677 and CC3435).
Haplotype analysis revealed that patients who received their graft from a donor carrying the TTT haplotype had an increased risk of graft loss compared to those whose grafts came from a CGC haplotype carrier (HR 2.616; 95 CI (1.373 4.986); p 0.0035) ( ). Table 3 recipients sex or age, donor s sex or age, cold ischemia time or number of HLA mismatches was found ( ).
' ' Table 3 Independent risk factors for graft loss: multivariate analysis Only the donor s G2677T SNP and acute rejection remained significant in the final multivariate Cox model ( ). ' ABCB1 Table 4 Patients who received their graft from a donor carrying the 2677TT or the G2677T genotype had a graft loss hazard ratio of 12.0 and 4.7, respectively as compared to those transplanted from carriers of the GG2677 genotype. Simultaneously, patients who had at least one episode of acute rejection had a graft loss hazard ratio of 3.1 as compared to those who did not experience acute rejection.
In the final Cox model including the donor s haplotype instead of the SNPs, again only the haplotype and ' ABCB1 ABCB1 ABCB1
acute rejection remained significant. Patients who received their graft from a donor homozygous or heterozygous for the variant ABCB1 (TTT) haplotype had a graft loss hazard ratio of 9.3 and 3.3, respectively, as compared to those transplanted from carriers of other haplotype combinations ( ). Simultaneously, patients who had had at least one acute rejection episode had a graft loss hazard ratio Table 4 of 2.8 as compared to those with no acute rejection episode.
Survival analysis further confirmed that the cumulative incidence of graft loss was significantly higher when donors carried the TTT haplotype (p 0.0028) (
). ABCB1 = Figure 1 
Association of ABCB1 haplotype with renal function
A significantly more important decrease of creatinine clearance over the follow-up period ( CrCl/y) was observed when donors were Δ carriers of the variant TTT haplotype (homozygotes for TTT:
3.047 4.008 mL.min per year, heterozygotes for TTT: 
when regression analysis of creatinine clearance measured annually was performed and the average slope was compared between the different haplotype groups (data not shown).
Discussion
Based on the data collected retrospectively in 259 renal transplant patients receiving CsA with a mean follow-up of 72 months (range:
8 to 190 months), we found that the 1236T, 2677T and 3435T variant alleles and the corresponding (1236T-2677T-3435T) variant ABCB1 haplotype in graft donors were associated with a higher risk of graft loss. Multivariate analysis considering this haplotype, the CYP3A5 *3 and polymorphisms recipients demographic characteristics, donors age and sex, graft cold ischemia time, number of HLA CYP3A4 *1B ' ' mismatches, and occurrence of acute rejection identified the variant haplotype and acute rejection as the only significant ABCB1 predictors of long-term graft survival. Moreover, the decrease in renal function over the follow-up period (estimated as delta creatinine clearance per year) was more pronounced when the donor was carrier of the TTT haplotype. ABCB1
This study was based on a long-term collection of donors DNA samples by the Immunology laboratory of Limoges University ' Hospital and was based on the hypothesis that polymorphisms of the donor s P-gp or CYP3A proteins (reflecting their local activity in the ' kidney graft) could influence CsA long-term nephrotoxicity and finally graft loss. P-gp acts as a transport pump actively excreting CsA from the epithelial tubular cells into urine. As it is abundantly expressed in these cells, normal P-gp activity in the graft may protect them from CsA toxicity. significantly linked to the outcome due to important epithelial chimerism after renal transplantation. Although no association between polymorphism and graft survival was found at 3 years, they suggested that a longer follow-up would be necessary to observe the ABCB1 progression from chronic histological damage to renal graft loss. Our retrospective study provides convincing evidence of the importance of the donor s genotype on graft loss in renal transplant patients on CsA with long-term follow-up. Moreover, the analysis of the ' ABCB1 evolution of renal function showed that when the donor carried the TTT haplotype creatinine clearance declined more rapidly, ABCB1 leading to a shorter time to graft loss. It is noteworthy that we did not observe a gradual change of renal function with haplotype copy number. A possible explanation is that creatinine clearance is a continuous variable subject to high variability, and that the number of TTT homozygotes was too low as compared to heterozygotes to observe a potential additive effect.
Cattaneo
recently found that recipients carriers of the T allelic variants of exons 21 and 26 had an increased risk for CsA-related et al.
adverse events, including delayed graft function and lower GFR ( ). In the present study, the analysis of recipient DNA polymorphisms 17 was performed on 9 graft loss episodes only, because 11 recipients with graft loss died before the beginning of this retrospective study, i.e.
before we could collect their DNA (these patients were amongst those transplanted farthest back in time and graft loss may have shortened their survival). We found no association between recipient haplotype and graft loss (data not shown) but the low number of events ABCB1 makes any conclusion difficult to drawn.
In addition to polymorphism, multivariate analysis identified acute rejection as another, already well-known (  ),  ABCB1 18 -20 independent factor of graft loss, however with lower hazard ratio values than the polymorphisms or haplotype. ABCB1
There are some limitations to this study. First, there is a lack of an independent validation group. It is rare to find recipients with long-term follow-up data for whom donor DNA is available as can be seen by the paucity of studies in this domain ( , ) . When such 21 22 data exist, there is a short retrospective follow-up of recipients ( , ). Despite our efforts and contacts with colleagues, we have been 9 16 unable to find an independent database with a follow-up period as long as for our recipients.
Secondly, we missed data on immunosuppressant blood concentrations, in particular CsA, due to the impossibility to reliably retrieve these data retrospectively over such a long period of time. Third, precise histological analysis of explanted grafts is missing. Out of the 28 patients who lost their graft, 8 were excluded from the analysis owing to graft loss attributable to clear external causes. The 20 patients remaining had a graft biopsy at one point in time during the follow-up period. Seventeen of these biopsies allowed histological analysis of the graft and most (12/17) showed histological damages compatible with CsA toxicity. Unfortunately, case-control comparisons on histological findings in the whole cohort could not be undertaken because biopsies were not performed in a majority of patients. Finally, it Donor s P-gp polymorphisms and graft loss ' Clin Pharmacol Ther . Author manuscript Page / 4 8 is evident that graft loss is the result of multiple other factors, the study of which was beyond the goal of the present work that specifically aimed to investigate the role of genetic factors from the donor in the occurrence of graft loss, owing to its retrospective design that made it possible to study this rare and late occurring event.
In conclusion, we found that the variant haplotype of graft donors is associated with a significantly higher risk of graft loss in ABCB1 kidney transplant recipients. It suggests that genetic variations in are predictive of graft outcomes through P-gp influence on local ABCB1
CsA concentration. Our study provides additional and complementary evidence to the results of Naesens who showed that in patients et al.
receiving calcineurin inhibitors polymorphisms are predictive of the renal graft deterioration independently of graft quality at ABCB1 transplantation ( ). Owing to developments in genetic technology for clinical use, it can be proposed that genotyping for be 16 ABCB1
included as part of systematic genotyping of the donor in routine practice and that the donor haplotype be taken in account in the ABCB1 choice or the doses of the immunosuppressants.
Methods
Patient population
The clinical data-on-file from renal graft recipients between 1990 and 2005, routinely followed as outpatients at Limoges University hospital were retrospectively studied. The ethics committee of Limoges hospital approved the protocol. Informed consent was obtained from each living patient, while French Health Authorities have waived the requirement for consent for deceased patients and donors. The following inclusion criteria were used: recipient age > 18 years; kidney graft from a cadaveric donor (following brain death); patients treated with CsA (SANDIMMUN or NEORAL ); functional graft after more than one year posttransplantation; donor s DNA available.
The exclusion criteria were: patient age < 18 years; pregnancy; combined kidney and pancreas, heart or liver transplantation; patient treated with tacrolimus or an mTOR inhibitor; graft survival < 1 year so as to exclude precocious graft loss, which is not due to nephrotoxicity. Eight patients were excluded from the analysis because they lost their graft as a consequence of a clearly identified cause: was estimated by subtracting the last creatinine clearance value available to the value at one year posttransplantation divided by follow-up duration (delta creatinine clearance per year). The only data available for donors was age and sex.
Donors DNA bank '
Each donor s genomic DNA was extracted from lymph nodes or spleen lymphocytes by salting out extraction as previously described ( ' ) and banked by the Immunology laboratory of Limoges University Hospital as part of routine practice. 23 SNPs, and 1236 C>T (exon 12, rs1128503), 2677 G>T (exon 21, rs2032582) and 3435 C>T (exon 26, rs1045642) SNPs were ABCB1 determined using TaqMan allelic discrimination assays on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Courtaboeuf, France). Primers and probes were purchased from Applied-Biosystems as validated custom or DME assays.
Identification of genotypes
Statistical analyses
Deviations from the Hardy-Weinberg equilibrium were studied using the Fisher s exact test. The effect of gene polymorphisms (SNPs ' or haplotypes) on graft loss was investigated using the Cox proportional hazard model. P values less than 0.05 were considered significant and 95 confidence intervals were calculated when relevant. For SNPs and haplotypes association analyses, the most frequent allele was % considered as the reference. For multivariate analysis, the significance of variables in the final model was tested by a backward stepwise process using the likelihood ratio to evaluate the effect of omitting variables.
After studying the effect of each polymorphism independently, the association of haplotypes with graft loss was analyzed using the The most probable haplotypes were inferred for each patient using the PHASE V2.0 program ( ) and for the significant 25 polymorphisms, time-to-event data were estimated using Kaplan-Meier analysis for patient with or without the polymorphism of interest, and groups were compared using the log-rank test.
One way analysis of variance (ANOVA) was performed to test the influence of significant polymorphisms on delta creatinine clearance per year.
All statistical analyses were performed using Statview 5.0 (SAS Institute Inc, Cary, NC, USA), except when stated otherwise. 
